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PreviewsThe diversity of mammalian Hsp70
functions makes this protein family, in
isolation, a poor target for therapeutics.
The central importance of J-proteins in
defining Hsp70 activity offers both the
promise of and a significant challenge to
developing small molecule strategies to
alter Hsp70 function in vivo: identifying
molecules that specifically inhibit the
Hsp70-J-protein complex. In this issue
of Chemistry and Biology, Chang et al.
(2011) describe a screening approach to
identify molecules that specifically inhibit
the J-protein-induced stimulation of
Hsp70 ATPase activity. Specifically, the
authors present what they refer to as
‘‘gray box screening,’’ which focuses on
identifying small molecules that target
emergent properties of a fully reconsti-
tuted biological pathway.
The authors screened a reconstituted
bacterial Hsp70 pathway including the
Hsp70, J-protein, and NEF homologs
DnaK, DnaJ, and GrpE, respectively.
Specifically, the authors focused on iden-
tifying small molecules that selectively
inhibited the DnaJ-stimulated ATPase
activity of DnaK. Interestingly, when
screening against plant extracts, they
identified the flavonoid myricetin as
a potent inhibitor of DnaJ-dependent
DnaK ATPase activity. Importantly, myri-
cetin did not inhibit the basal DnaK
ATPase activity nor GrpE-mediated nucle-otide exchange, suggesting that it selec-
tively intervenes in DnaJ-dependent
steps of the DnaK chaperone cycle
(Figure 1). NMR analysis revealed that
myricetin bound at a unique site on the
NBD of DnaK, distinct from both the
nucleotide binding site and the DnaJ
binding site. Through biophysical
approaches, the authors demonstrated
that myricetin binding to the novel site
allosterically inhibited DnaJ binding, and
selectively disrupted DnaJ-dependent
ATPase stimulation. Critically, this is
a ligand binding site that could not have
been discovered through traditional
screening using DnaK alone.
The identification of a small-molecule
based screening approach to identify
specific inhibitors of the Hsp70-J-protein
interactions puts forward the tantalizing
possibility of identifying small molecules
that can target specific Hsp70-J-protein
interactions, allowing selective modula-
tion of Hsp70 activity in vivo. Although
the chemical properties of myricetin
preclude its use in drug development,
the identification of the novel myricetin
binding pocket offers a new target for
small molecule drug design. A vital next
step will be the extension to mammalian
J-domain protein-Hsp70 interactions,
wherein the critical goal will be to achieve
discrimination between J-domain binding
partners by small molecule regulators ofChemistry & Biology 18, February 25, 2011Hsp70. This is the test that will both deter-
mine the therapeutic potential of, as well
as pose the greatest challenge to, this
screening strategy.
Beyond the details of the Hsp70
system, the authors provide a proof-of-
principle, demonstrating the utility of their
gray box screening approach to identify
small molecules targeting specific emer-
gent properties of a protein complex.
While the heterogeneity and sheer size
ofmany biological pathways—particularly
those that lack binding-induced enzy-
matic activity—may preclude the general
application of gray box screening, smaller
and better characterized pathways such
as those between Hsp70 and its cocha-
perones will benefit from this approach.REFERENCES
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Cystic fibrosis transmembrane conductance regulator (CFTR) correctors are small molecules that target the
most common cause of cystic fibrosis: misfolded F508del-CFTR. Using differential scanning fluorimetry,
Sampson et al. (2010) identify a CFTR corrector that interacts directly with the CFTR domain affected by
the F508del mutation.Two decades after the identification of
the defective gene responsible for cystic
fibrosis (CF), symptomatic treatment
remains the bedrock of CF patient care.
However, there is optimism in the CFcommunity that this might change shortly.
By exploiting knowledge and under-
standing of the cystic fibrosis transmem-
brane conductance regulator (CFTR) Cl
channel, its physiological role, anddysfunction in CF, the CF community
now stands at the cusp of developing
therapeutics that target the root cause of
the disease. The latest milestone in this
quest was the successful completion ofª2011 Elsevier Ltd All rights reserved 145
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Previewsthe first clinical trial of a CFTR potentiator,
a small molecule designed to rescue the
defective function of mutant CFTR
present at its correct cellular location,
the apical membrane of epithelial cells
lining ducts and tubes throughout the
body (Accurso et al., 2010). But fixing
defects in CFTR function is only part of
the problem in CF.
The molecular basis of most cases of
CF is temperature-sensitive protein mis-
folding caused by the deletion of the
phenylalanine residue at position 508 of
the CFTR protein sequence; 90% of CF
patients carry at least one copy of the
F508del mutation. Because misfolded
F508del-CFTR is retained in the endo-
plasmic reticulum at normal body temper-
ature and degraded by the proteasome,
the vast majority of F508del-CFTR fails
to traffic to the apical membrane of
epithelia (for review, see Riordan, 2008).
The small amount of F508del-CFTR that
reaches the apical membrane forms
unstable CI channels with a pronounced
defect in channel gating (the pattern of
channel opening and closing). Thus, small
molecules with two types of activity are
required to restore function to F508del-
CFTR: first, CFTR correctors, so called
because they overcome the processing
defect of F508del-CFTR and deliver the
mutant protein to the apical membrane;
and second, CFTR potentiators, so called
because they enhance ATP-dependent
channel gating following CFTR phosphor-
ylation by protein kinase A (PKA) but
do not open quiescent CFTR Cl chan-
nels. To date, very few molecules have
been identified with both types of activity,
although intensive efforts are being
made to develop such molecules, termed
CFTR corrector-potentiators or dual-
acting molecules.
The strategy of choice to identify CFTR
correctors is high-throughput screening
(HTS) because there is insufficient infor-
mation at the current time to design ratio-
nally CFTR correctors. HTS exploits a reli-
able, sensitive, cost-effective assay to
screen libraries of drug-like compounds
to identify lead compounds for medicinal
chemistry optimization. Using heterolo-
gous epithelial cells coexpressing
F508del-CFTR and a green fluorescent
protein with ultra-high halide sensitivity,
Pedemonte et al. (2005) identified the
bisaminomethylbithiazole corr-4a in a
screen of 150,000 drug-like chemicals.146 Chemistry & Biology 18, February 25, 201Corr-4a has established itself as the
benchmark against which all other CFTR
correctors are tested. It is equipotent to
low temperature at restoring CFTR func-
tion to CF epithelia (genotype F508del/
F508del), achieving levels of CFTR func-
tion about 8% of that of normal airway
epithelia (Pedemonte et al., 2005). Resto-
ration of this amount of CFTR function
using in vitro assays is considered to
have a therapeutic benefit, although we
really do not know how much CFTR is
enough. Critically, it will be necessary to
improve the disease biomarkers and ther-
apeutic endpoints used in clinical trials to
address this question.
At the present time, the mechanisms
of action of CFTR correctors are not
completely understood. These agents
might interact with CFTR itself, by acting
as either substrate mimics or active site
inhibitors. Alternatively, they might target
one or more of the bewildering array of
CFTR-interacting proteins that orches-
trate and control the biosynthesis of
CFTR, its delivery to, and its expression
at the apical membrane. Targeting regula-
tors of protein synthesis, sorting, and
trafficking might unleash all manner of
cellular havoc. It therefore seems far
better to target CFTR itself to achieve
drug specificity. Previous work suggests
that some CFTR correctors might indeed
interact directly with CFTR. For example,
the CFTR potentiator VRT-532 (Van Goor
et al., 2006) rescues the misprocessing
of F508del-CFTR (indicating that it’s a
dual-acting molecule), whereas it is with-
out effect on a misprocessing mutant in
P-glycoprotein, a closely related ATP-
binding cassette (ABC) transporter
(Wang et al., 2006). Moreover, the CFTR
corrector VRT-325 (Van Goor et al.,
2006) inhibited anion transport by low
temperature-rescued F508del-CFTR and
diminished the apparent ATP affinity of
purified reconstituted F508del-CFTR
protein (Kim Chiaw et al., 2010). However,
both VRT-325 and VRT-532 have toxic
effects on cells, making them unsuitable
lead compounds for drug development.
In this issue of Chemistry & Biology,
Sampson et al. (2011) identify the CFTR
corrector RDR1 that targets directly the
first nucleotide-binding domain (NBD1),
the location of the F508del mutation in
CFTR. The authors employ an innovative
method for drug discovery: differential
scanning fluorimetry, which identifies1 ª2011 Elsevier Ltd All rights reservedligands of a target protein by monitoring
their effects on the thermal unfolding of
the protein. Among 224 hits identified in
a previous HTS for CFTR correctors, just
one chemical, the substituted phenylhy-
drazone RDR1, thermally stabilized
murine F508del-NBD1 (Sampson et al.,
2011). As with previous studies by the
Hanrahan and Thomas groups, a battery
of biochemical and physiological assays
are deployed to investigate F508del-
CFTR rescue by RDR1 in heterologous
cells, polarized epithelia, and geneti-
cally-engineered mice. The authors’ data
demonstrate that RDR1 thermally stabi-
lizes murine F508del-NBD1, increases
the maturation of human F508del CFTR-
protein, and augments the function of
human F508del-CFTR in vitro and murine
F508del-CFTR in vivo. Taken together,
these data and the additivity of RDR1
treatment and low-temperature incuba-
tion on human F508del-CFTR maturation
argue convincingly that RDR1 is a CFTR
corrector that targets directly F508del-
NBD1 to exert its effects.
Sampson et al. (2011) demonstrate that
RDR1 thermally stabilizes murine
F508del-NBD1 in a manner similar to
ATP, but binds to the protein at a site
distinct from that of ATP. Because CFTR
potentiators (e.g., genistein) (Moran
et al., 2005) bind at a site on NBD1 distinct
from ATP and because RDR1 itself poten-
tiates weakly F508del-CFTR Cl- currents
in polarized epithelia (Sampson et al.,
2011), the authors investigate whether
the CFTR potentiators capsaicin, genis-
tein, and VRT-532 thermally stabilize
murine F508del-NBD1. Capsaicin and
genistein were without effect, whereas
elevated concentrations of VRT-532
induced limited thermal stabilization of
murine F508del-NBD1 (Sampson et al.,
2011). One interpretation of these data is
that the binding site for RDR1 on NBD1
might be distinct from the NBD1:NBD2
dimer interface, the location of the two
ATP-binding sites, and one location
where CFTR potentiators dock (Figure 1).
Indeed, it is tempting to speculate that
RDR1 might bind in the vicinity of F508
at the interface between the NBDs and
the membrane-spanning domains that
form the CFTR pore, where a ligand-
binding site has been identified by
in silico structure-based screening (Kalid
et al., 2010) (Figure 1). But equally, it is
important to emphasize that there are
Figure 1. General Location of Some Drug-Binding Sites in CFTR
The simplified model shows the organization of the NBD1:NBD2 dimer in an open CFTR Cl channel.
Located at the dimer interface, two ATP-binding sites (sites 1 and 2) are formed by the Walker A and B
motifs (labeled A and B, respectively) of one NBD and the LSGGQmotifs of the other NBD. Site 2 contains
a canonical LSGGQmotif, whereas site 1 contains a noncanonical LSGGQmotif (LSHGH). The position of
F508del (surface of NBD1 opposing intracellular loop 4 [ICL4]) is shown by an asterisk, while the general
location of two drug-binding sites is indicated by dotted lines. Some CFTR potentiators bind at the dimer
interface at a location distinct from the two ATP-binding sites (labeled 1) (Moran et al., 2005). A binding site
for CFTR correctors and potentiators has also been identified at the interface between NBD1 andMSD2 in
the vicinity of F508 and ICL4 (labeled 2) (Kalid et al., 2010). MSD, membrane-spanning domain; NBD,
nucleotide-binding domain; P, phosphorylation of the RD; Pi, inorganic phosphate; RD, regulatory
domain. ‘‘In’’ and ‘‘Out’’ denote the intra- and extracellular sides of the membrane, respectively. See
the text and Hwang and Sheppard (2009) for further information. Modified with permission from Hwang
and Sheppard (2009).
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Previewsnotable differences in the molecular phar-
macology of human and murine CFTR
(Scott-Ward et al., 2007) that urge caution
when interpreting these data. Clearly,
identification of the RDR1-binding site
on CFTR will be a high priority for future
research.
A further important priority for future
work is to determine whether RDR1 treat-
ment alleviates the defective channel
gating of F508del-CFTR. Once phosphor-
ylated by PKA, wild-typeCFTRwill chatter
open and closed seemingly indefinitely
in the presence of intracellular MgATP.
By contrast, following low -temperature
correction, F508del-CFTR is an indolentchannel that soon refuses to open
no matter how much it is cajoled. In
previous work (e.g., Pissarra et al., 2008),
we demonstrated that rescue of
F508del-CFTR by second site mutations
in cis with F508del abrogated, albeit
not completely, the gating defect of
F508del-CFTR, but had little effect on
channel ‘‘rundown’’ (irreversible loss of
channel activity). It is therefore critical to
learn the effects of RDR1 treatment on
the gating behavior and channel stability
of F508del-CFTR. If RDR1 not only traffics
F508del-CFTR to the cell surface, but
restores to it the gating behavior of
wild-type CFTR and prevents channelChemistry & Biology 18, February 25, 2011‘‘rundown,’’ we should celebrate! This
would be compelling evidence for RDR1
treatment correcting themisfolding defect
of F508del-CFTR.REFERENCES
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